Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Aug;34(2):130–138. doi: 10.1111/j.1365-2125.1992.tb04121.x

The analgesic activity of morphine-6-glucuronide.

R Osborne 1, P Thompson 1, S Joel 1, D Trew 1, N Patel 1, M Slevin 1
PMCID: PMC1381529  PMID: 1419474

Abstract

1. The pharmacokinetics, cardio-respiratory effects and analgesic effects of intravenous morphine-6-glucuronide were studied in 20 cancer patients with pain. Four different dose levels (0.5, 1, 2, and 4 mg 70 kg-1) were studied. Plasma concentrations of morphine-6-glucuronide were measured for 12 h after dosing. Pulse rate, respiratory rate and blood pressure were monitored, and pain relief was measured using two rating scales and a visual analogue scale. 2. The mean elimination half-life (+/- s.d.) of morphine-6-glucuronide was 3.2 +/- 1.6 h. The mean AUC standardised to a dose of 1 mg 70 kg-1 was 390 +/- 263 nmol l-1 h. Mean morphine-6-glucuronide clearance was 96 +/- 38 ml min-1. There was a direct relationship between morphine-6-glucuronide plasma clearance and calculated creatinine clearance (r = 0.81, P less than 0.001). 38 +/- 22% of the dose of morphine-6-glucuronide was recovered unchanged in the urine in 24 h. No morphine or morphine-3-glucuronide was detected in the plasma or urine of any patient after morphine-6-glucuronide treatment. 3. Morphine-6-glucuronide exerted a useful analgesic effect in 17/19 assessable patients for periods ranging between 2 and 24 h. No correlation was observed between dose or plasma morphine-6-glucuronide concentrations, and duration or degree of analgesia. No clinically significant changes in cardio-respiratory parameters were observed. No patients reported sedation or euphoria. Nausea and vomiting were notably absent in all cases. 4. Morphine-6-glucuronide is an effective and well-tolerated analgesic. It is likely that the majority of the therapeutic benefit of morphine is mediated by morphine-6-glucuronide.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
130

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodd E., Jacobsen D., Lund E., Ripel A., Mørland J., Wiik-Larsen E. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol. 1990 Sep;9(5):317–321. doi: 10.1177/096032719000900509. [DOI] [PubMed] [Google Scholar]
  2. Boerner U. The metabolism of morphine and heroin in man. Drug Metab Rev. 1975;4(1):39–73. doi: 10.3109/03602537508993748. [DOI] [PubMed] [Google Scholar]
  3. Brown C. E., Roerig S. C., Burger V. T., Cody R. B., Jr, Fujimoto J. M. Analgesic potencies of morphine 3- and 6-sulfates after intracerebroventricular administration in mice: relationship to structural characteristics defined by mass spectrometry and nuclear magnetic resonance. J Pharm Sci. 1985 Aug;74(8):821–824. doi: 10.1002/jps.2600740804. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Hanna M. H., Peat S. J., Knibb A. A., Fung C. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br J Anaesth. 1991 Jan;66(1):103–107. doi: 10.1093/bja/66.1.103. [DOI] [PubMed] [Google Scholar]
  6. Hanna M. H., Peat S. J., Woodham M., Knibb A., Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth. 1990 May;64(5):547–550. doi: 10.1093/bja/64.5.547. [DOI] [PubMed] [Google Scholar]
  7. JANSSEN P. A. A review of the chemical features associated with strong morphine-like activity. Br J Anaesth. 1962 Apr;34:260–268. doi: 10.1093/bja/34.4.260. [DOI] [PubMed] [Google Scholar]
  8. Joel S. P., Osborne R. J., Slevin M. L. An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J Chromatogr. 1988 Sep 9;430(2):394–399. doi: 10.1016/s0378-4347(00)83176-x. [DOI] [PubMed] [Google Scholar]
  9. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  10. Littman G. S., Walker B. R., Schneider B. E. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther. 1985 Jul;38(1):16–23. doi: 10.1038/clpt.1985.127. [DOI] [PubMed] [Google Scholar]
  11. Mori M., Oguri K., Yoshimura H., Shimomura K., Kamata O. Chemical synthesis and analgesic effect of morphine ethereal sulfates. Life Sci I. 1972 Jun 1;11(11):525–533. doi: 10.1016/0024-3205(72)90003-3. [DOI] [PubMed] [Google Scholar]
  12. Nordberg G., Borg L., Hedner T., Mellstrand T. CSF and plasma pharmacokinetics of intramuscular morphine. Eur J Clin Pharmacol. 1985;27(6):677–681. doi: 10.1007/BF00547048. [DOI] [PubMed] [Google Scholar]
  13. Oguri K., Ida S., Yoshimura H., Tsukamoto H. Metabolism of drugs. LXIX. Studies on the urinary metabolites of morphine in several mammlian species. Chem Pharm Bull (Tokyo) 1970 Dec;18(12):2414–2419. doi: 10.1248/cpb.18.2414. [DOI] [PubMed] [Google Scholar]
  14. Oguri K., Yamada-Mori I., Shigezane J., Hirano T., Yoshimura H. Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci. 1987 Sep 21;41(12):1457–1464. doi: 10.1016/0024-3205(87)90710-7. [DOI] [PubMed] [Google Scholar]
  15. Osborne R. J., Joel S. P., Slevin M. L. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 1986 Jun 14;292(6535):1548–1549. doi: 10.1136/bmj.292.6535.1548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Osborne R., Joel S., Trew D., Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet. 1988 Apr 9;1(8589):828–828. doi: 10.1016/s0140-6736(88)91691-1. [DOI] [PubMed] [Google Scholar]
  17. Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990 Jan;47(1):12–19. doi: 10.1038/clpt.1990.2. [DOI] [PubMed] [Google Scholar]
  18. Pasternak G. W., Bodnar R. J., Clark J. A., Inturrisi C. E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987 Dec 28;41(26):2845–2849. doi: 10.1016/0024-3205(87)90431-0. [DOI] [PubMed] [Google Scholar]
  19. Pasternak G. W., Childers S. R., Snyder S. H. Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. Science. 1980 May 2;208(4443):514–516. doi: 10.1126/science.6245448. [DOI] [PubMed] [Google Scholar]
  20. Pasternak G. W., Wood P. J. Multiple mu opiate receptors. Life Sci. 1986 May 26;38(21):1889–1898. doi: 10.1016/0024-3205(86)90217-1. [DOI] [PubMed] [Google Scholar]
  21. Rigg J. R. Ventilatory effects and plasma concentration of morphine in man. Br J Anaesth. 1978 Aug;50(8):759–765. doi: 10.1093/bja/50.8.759. [DOI] [PubMed] [Google Scholar]
  22. Rothman R. B., Jacobson A. E., Rice K. C., Herkenham M. Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824. Peptides. 1987 Nov-Dec;8(6):1015–1021. doi: 10.1016/0196-9781(87)90130-6. [DOI] [PubMed] [Google Scholar]
  23. Samuelsson H., Nordberg G., Hedner T., Lindqvist J. CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. Pain. 1987 Sep;30(3):303–310. doi: 10.1016/0304-3959(87)90018-2. [DOI] [PubMed] [Google Scholar]
  24. Shimomura K., Kamata O., Ueki S., Ida S., Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med. 1971 Sep;105(1):45–52. doi: 10.1620/tjem.105.45. [DOI] [PubMed] [Google Scholar]
  25. Svensson J. O., Rane A., Säwe J., Sjöqvist F. Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr. 1982 Jul 9;230(2):427–432. doi: 10.1016/s0378-4347(00)80494-6. [DOI] [PubMed] [Google Scholar]
  26. Säwe J., Dahlström B., Rane A. Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol. 1983;24(4):537–542. doi: 10.1007/BF00609900. [DOI] [PubMed] [Google Scholar]
  27. Thorpe D. H. Opiate structure and activity--a guide to understanding the receptor. Anesth Analg. 1984 Feb;63(2):143–151. [PubMed] [Google Scholar]
  28. Vater M., Smith G., Aherne G. W., Aitkenhead A. R. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth. 1984 Aug;56(8):821–827. doi: 10.1093/bja/56.8.821. [DOI] [PubMed] [Google Scholar]
  29. WOODS L. A. Distribution and fate of morphine in non-tolerant and tolerant dogs and rats. J Pharmacol Exp Ther. 1954 Oct;112(2):158–175. [PubMed] [Google Scholar]
  30. Yoshimura H., Oguri K., Tsukamoto H. Metabolism of drugs. LX. The synthesis of codeine and morphine glucuronides. Chem Pharm Bull (Tokyo) 1968 Nov;16(11):2114–2119. doi: 10.1248/cpb.16.2114. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES